Case Report
Copyright ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Feb 16, 2021; 9(5): 1175-1183
Published online Feb 16, 2021. doi: 10.12998/wjcc.v9.i5.1175
Venetoclax in combination with chidamide and dexamethasone in relapsed/refractory primary plasma cell leukemia without t(11;14): A case report
Yang Yang, Li-Juan Fu, Chun-Mei Chen, Mei-Wei Hu
Yang Yang, Li-Juan Fu, Chun-Mei Chen, Mei-Wei Hu, Department of Hematology, The Second Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou 310014, Zhejiang Province, China
Author contributions: Yang Y drafted the manuscript; Hu MW reviewed the literature and revised manuscript; Chen CM reviewed the literature; Fu LJ collected the data; All authors issued final approval for the version to be submitted.
Informed consent statement: Informed written consent was obtained from the patient for publication of this report and any accompanying images.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Mei-Wei Hu, MSc, Associate Chief Physician, Department of Hematology, The Second Affiliated Hospital of Zhejiang Chinese Medical University, No. 318 Chaowang Road, Hangzhou 310014, Zhejiang Province, China. humweiwei@sina.cn
Received: October 30, 2020
Peer-review started: October 30, 2020
First decision: November 20, 2020
Revised: December 4, 2020
Accepted: December 16, 2020
Article in press: December 16, 2020
Published online: February 16, 2021
Processing time: 92 Days and 6.9 Hours
Core Tip

Core Tip: Primary plasma cell leukemia is a rare and high mortality disease. We herein described a case report of relapsed/refractory primary plasma cell leukemia without t(11;14) who achieved a very good partial response from venetoclax therapy in combination with chidamide and dexamethasone.